Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer
- 1 March 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (5), 1464-1471
- https://doi.org/10.1158/1078-0432.ccr-11-2485
Abstract
Purpose: Cervical tumor response on posttherapy 2[18F]fluoro-2-deoxy-d-glucose-positron emission tomography (FDG-PET) is predictive of survival outcome. The purpose of this study was to use gene expression profiling to identify pathways associated with tumor metabolic response. Experimental Design: This was a prospective tissue collection study for gene expression profiling of 62 pretreatment biopsies from patients with advanced cervical cancer. Patients were treated with definitive radiation. Fifty-three patients received concurrent chemotherapy. All patients underwent a pretreatment and a 3-month posttherapy FDG-PET/computed tomography (CT). Tumor RNA was harvested from fresh frozen tissue and hybridized to Affymetrix U133Plus2 GeneChips. Gene set enrichment analysis (GSEA) was used to identify signaling pathways associated with tumor metabolic response. Immunohistochemistry and in vitro FDG uptake assays were used to confirm our results. Results: There were 40 biopsies from patients with a complete metabolic response (PET-negative group) and 22 biopsies from patients with incomplete metabolic response (PET-positive group). The 3-year cause-specific survival estimates were 98% for the PET-negative group and 39% for the PET-positive group (P < 0.0001). GSEA identified alterations in expression of genes associated with the PI3K/Akt signaling pathway in patients with a positive follow-up PET. Immunohistochemistry using a tissue microarray of 174 pretreatment biopsies confirmed p-Akt as a biomarker for poor prognosis in cervical cancer. The phosphoinositide 3-kinase (PI3K) inhibitor LY294002 inhibited FDG uptake in vitro in cervical cancer cell lines. Conclusions: Activation of the PI3K/Akt pathway is associated with incomplete metabolic response in cervical cancer. Targeted inhibition of PI3K/Akt may improve response to chemoradiation. Clin Cancer Res; 18(5); 1464–71. ©2012 AACR.Keywords
This publication has 27 references indexed in Scilit:
- PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitroMolecular Cancer, 2011
- Phosphatidylinositol 3-Kinase Inhibition by LY294002 Radiosensitizes Human Cervical Cancer Cell LinesClinical Cancer Research, 2006
- Preoperative lymph node staging of early‐stage cervical carcinoma by [18F]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomographyCancer, 2005
- Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysisInternational Journal of Radiation Oncology*Biology*Physics, 2004
- The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human GliomasJournal of Clinical Oncology, 2004
- Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01Journal of Clinical Oncology, 2004
- Posttherapy surveillance monitoring of cervical cancer by FDG-PETInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Classification of Sensitivity or Resistance of Cervical Cancers to Ionizing Radiation According to Expression Profiles of 62 Genes Selected by cDNA Microarray AnalysisNeoplasia, 2002
- Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the CervixJournal of Clinical Oncology, 2001
- Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical CancerThe New England Journal of Medicine, 1999